Author of

• 11692

  +

  P2.10 - Poster Session 2 - Chemotherapy (ID 207)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11744

    +

    P2.10-052 - A Feasibility Study of Vinorelbine and Bevacizumab in Patients with Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (ID 2152)

    09:30 - 09:30  |  Author(s): A. Yamamoto
    • Abstract

    Background
    In recent clinical trials for non-squamous non-small cell lung cancer (NonSq-NSCLC), platinum regimens with bevacizumab (BEV) resulted in better prognosis and acceptable toxicity profile. However, there have been few studies on their feasibility or efficacy of BEV in NonSq-NSCLC patients who were previously treated with a platinum regimen. Therefore, we conducted a prospective study of combination therapy with vinorelbine (VNR) and BEV in NonSq-NSCLC patients who were previously treated with a platinum regimen.

    Methods
    Eligible patients had recurrent NonSq-NSCLC, PS 0-1, and adequate organ functions. The primary endpoint was feasibility. Secondary endpoints were response rate and safety. Patients received combination therapy with VNR (25mg/kg on day 1, 8) and BEV (15mg/kg, day 1). The treatment cycles were repeated every 3 weeks until progressive disease (PD)

    Results
    From June 2011 to January 2013, 15 NSCLC patients were eligible for this study. The patients consisted of 7 men and 8 women, and their median age was 68 (range 57-82) years. The patients received the treatment with a median of 4 (range 1-12) cycles. The histological classification was adenocarcinoma in all. The PS (ECOG) was 0 in 2, 1 in 11, and 2 in 2, respectively. The incidence of grade 3-4 neutropenia, anemia, thrombocytopenia and febrile neutropenia was 26.7%, 6.7%, 6.7%, and 13.3%, respectively. Response rate and disease control rate in the overall study population (n=15) were 26.7% and 73.3%, respectively. Median PFS was 2.8 months. Grade 3-4 phlebitis occurred in 3 patients; phlebitis improved by central venous catheter in 1, and by administration with corticosteroid in other two patients.

    Conclusion
    Combination therapy with VNR and BEV was safe and effective in NonSq-NSCLC patients who were previously treated with a platinum regimen. However, a few patients had a risk of developing phlebitis.